Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.

ABSTRACT:

Purpose

To determine the effectiveness of adjuvant dendritic cell (DC) vaccination to induce tumor-specific immunological responses in stage III melanoma patients.

Experimental design

Retrospective analysis of stage III melanoma patients, vaccinated with autologous monocyte-derived DC loaded with tumor-associated antigens (TAA) gp100 and tyrosinase after radical lymph node dissection. Skin-test infiltrating lymphocytes (SKILs) obtained from delayed-type hypersensitivity skin-test biopsies were analyzed for the presence of TAA-specific CD8(+) T cells by tetrameric MHC-peptide complexes and by functional TAA-specific T cell assays, defined by peptide-recognition (T2 cells) and/or tumor-recognition (BLM and/or MEL624) with specific production of Th1 cytokines and no Th2 cytokin

SUBMITTER: Boudewijns S 

PROVIDER: S-EPMC5006921 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature